Browse SENP1

Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm. Note=Shuttles between cytoplasm and nucleus.
Domain PF02902 Ulp1 protease family
Function

Protease that catalyzes two essential functions in the SUMO pathway. The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins. The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein. Deconjugates SUMO1 from HIPK2 (PubMed:16253240). Deconjugates SUMO1 from HDAC1 and BHLHE40/DEC1, which decreases its transcriptional repression activity (PubMed:21829689). Deconjugates SUMO1 from CLOCK, which decreases its transcriptional activation activity (PubMed:23160374). Deconjugates SUMO2 from MTA1 (PubMed:21965678). Desumoylates CCAR2 which decreases its interaction with SIRT1 (PubMed:25406032). Deconjugates SUMO1 from GPS2 (PubMed:24943844).

> Gene Ontology
 
Biological Process GO:0002262 myeloid cell homeostasis
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0010724 regulation of definitive erythrocyte differentiation
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016925 protein sumoylation
GO:0016926 protein desumoylation
GO:0018205 peptidyl-lysine modification
GO:0030099 myeloid cell differentiation
GO:0030218 erythrocyte differentiation
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032844 regulation of homeostatic process
GO:0034101 erythrocyte homeostasis
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0045637 regulation of myeloid cell differentiation
GO:0045646 regulation of erythrocyte differentiation
GO:0045861 negative regulation of proteolysis
GO:0045862 positive regulation of proteolysis
GO:0048872 homeostasis of number of cells
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060216 definitive hemopoiesis
GO:0060318 definitive erythrocyte differentiation
GO:0061136 regulation of proteasomal protein catabolic process
GO:0070646 protein modification by small protein removal
GO:1901799 negative regulation of proteasomal protein catabolic process
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903051 negative regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:1903363 negative regulation of cellular protein catabolic process
GO:1903706 regulation of hemopoiesis
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0004175 endopeptidase activity
GO:0004197 cysteine-type endopeptidase activity
GO:0008234 cysteine-type peptidase activity
GO:0016929 SUMO-specific protease activity
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0070137 ubiquitin-like protein-specific endopeptidase activity
GO:0070139 SUMO-specific endopeptidase activity
Cellular Component GO:0005635 nuclear envelope
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0031965 nuclear membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-3215018: Processing and activation of SUMO
R-HSA-3065679: SUMO is proteolytically processed
R-HSA-2990846: SUMOylation
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SENP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SENP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 0.99; FDR: 0.041900 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SENP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1430.486
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2020.857
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0980.911
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3290.346
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5060.74
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1050.956
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0710.814
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1230.929
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0620.966
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5780.511
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2620.305
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.170.00681
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SENP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SENP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SENP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SENP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SENP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SENP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SENP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSENP1
NameSUMO1/sentrin specific peptidase 1
Aliases SUMO1/sentrin specific protease 1; SuPr-2; sentrin/SUMO-specific protease SENP1; Sentrin-specific protease 1
Chromosomal Location12q13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SENP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.